Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
6.13
0.00 (0.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cytek Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 201.21 | 193.02 | 164.04 | 127.95 | 92.84 | 57.88 | Upgrade
|
| Revenue Growth (YoY) | 9.88% | 17.67% | 28.20% | 37.82% | 60.39% | 930.36% | Upgrade
|
| Cost of Revenue | 90.71 | 83.59 | 63.06 | 48.81 | 41.13 | 29.21 | Upgrade
|
| Gross Profit | 110.5 | 109.43 | 100.97 | 79.14 | 51.71 | 28.67 | Upgrade
|
| Selling, General & Admin | 92.1 | 91.62 | 67.92 | 45.55 | 24.36 | 16.98 | Upgrade
|
| Research & Development | 40.55 | 44.15 | 34.86 | 24.44 | 13.69 | 8.93 | Upgrade
|
| Operating Expenses | 132.65 | 135.77 | 102.78 | 69.99 | 38.05 | 25.91 | Upgrade
|
| Operating Income | -22.15 | -26.35 | -1.8 | 9.16 | 13.66 | 2.76 | Upgrade
|
| Interest Expense | -1.09 | -2.07 | -2.57 | -1.74 | -0.33 | -0 | Upgrade
|
| Interest & Investment Income | 5.66 | 6.41 | 4.62 | 0.05 | 0.11 | 0.71 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 0.04 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 7.52 | 7.52 | 1.02 | -1.57 | 0.99 | 0.25 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.36 | 0.27 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -10.41 | -14.21 | 1.26 | 5.94 | 14.43 | 3.73 | Upgrade
|
| Merger & Restructuring Charges | -1.5 | -1.5 | - | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | - | -20.02 | Upgrade
|
| Pretax Income | -11.91 | -15.71 | 1.26 | 5.94 | 14.43 | -16.29 | Upgrade
|
| Income Tax Expense | -1.75 | -3.56 | -1.22 | 2.91 | -4.98 | 0.53 | Upgrade
|
| Earnings From Continuing Operations | -10.16 | -12.15 | 2.48 | 3.03 | 19.41 | -16.83 | Upgrade
|
| Minority Interest in Earnings | - | - | -0.09 | 0.03 | - | - | Upgrade
|
| Net Income | -10.16 | -12.15 | 2.39 | 3.05 | 19.41 | -16.83 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 3 | 16.2 | - | Upgrade
|
| Net Income to Common | -10.16 | -12.15 | 2.39 | 0.05 | 3.22 | -16.83 | Upgrade
|
| Net Income Growth | - | - | -21.65% | -84.27% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 132 | 135 | 135 | 77 | 29 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 132 | 135 | 139 | 82 | 33 | 28 | Upgrade
|
| Shares Change (YoY) | -2.89% | -2.37% | 69.93% | 150.13% | 16.71% | - | Upgrade
|
| EPS (Basic) | -0.08 | -0.09 | 0.02 | 0.00 | 0.11 | -0.60 | Upgrade
|
| EPS (Diluted) | -0.08 | -0.09 | 0.02 | 0.00 | 0.10 | -0.60 | Upgrade
|
| EPS Growth | - | - | 2691.52% | -99.36% | - | - | Upgrade
|
| Free Cash Flow | 28.76 | 0.63 | -21.98 | 0.27 | 13.61 | -14.72 | Upgrade
|
| Free Cash Flow Per Share | 0.22 | 0.00 | -0.16 | 0.00 | 0.42 | -0.53 | Upgrade
|
| Gross Margin | 54.92% | 56.69% | 61.56% | 61.86% | 55.70% | 49.54% | Upgrade
|
| Operating Margin | -11.01% | -13.65% | -1.10% | 7.16% | 14.71% | 4.77% | Upgrade
|
| Profit Margin | -5.05% | -6.29% | 1.46% | 0.04% | 3.46% | -29.07% | Upgrade
|
| Free Cash Flow Margin | 14.30% | 0.33% | -13.40% | 0.21% | 14.66% | -25.43% | Upgrade
|
| EBITDA | -15.16 | -20.3 | 0.69 | 10.4 | 14.26 | 3.07 | Upgrade
|
| EBITDA Margin | -7.53% | -10.52% | 0.42% | 8.13% | 15.36% | 5.31% | Upgrade
|
| D&A For EBITDA | 6.99 | 6.05 | 2.49 | 1.24 | 0.6 | 0.31 | Upgrade
|
| EBIT | -22.15 | -26.35 | -1.8 | 9.16 | 13.66 | 2.76 | Upgrade
|
| EBIT Margin | -11.01% | -13.65% | -1.10% | 7.16% | 14.71% | 4.77% | Upgrade
|
| Effective Tax Rate | - | - | - | 49.02% | - | - | Upgrade
|
| Revenue as Reported | 201.21 | 193.02 | 164.04 | 127.95 | 92.84 | 57.88 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.